

# Therapeutic Antibodies Market in China 2023

<https://marketpublishers.com/r/T1ED9C894718EN.html>

Date: May 2023

Pages: 35

Price: US\$ 675.00 (Single User License)

ID: T1ED9C894718EN

## Abstracts

Therapeutic antibodies are a type of medication that is designed to target specific proteins in the body that are involved in disease processes. They are typically made from human or animal cells that have been genetically engineered to produce antibodies that can recognize and bind to a specific target protein. Once bound to the target protein, therapeutic antibodies can either block its activity or trigger an immune response against it, depending on the specific mechanism of action. Therapeutic antibodies have been developed to treat a wide range of diseases, including cancer, autoimmune disorders, infectious diseases, and inflammatory conditions. They are often used in combination with other medications, such as chemotherapy or immunosuppressive drugs, to improve treatment outcomes and reduce side effects. The therapeutic antibodies market in China is likely to register a CAGR of over 26.95% with an incremental growth of USD 42.7 billion during the forecast period 2023-2029.

This industry report offers market estimates of the China market, followed by a detailed analysis of the type. The China market data on therapeutic antibodies can be segmented by type: antibody-drug conjugate (ADC), BsAb, monospecific Ab, others.

The China therapeutic antibodies market is highly competitive. As of 2022, the major players in the China therapeutic antibodies market were 3SBio Inc., Bristol-Myers Squibb Company, Chengdu Kanghong Pharmaceutical Group Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd., Merck & Co., Novartis International AG, Roche Holding AG, Sinopharm Corporation Ltd.

The data-centric report focuses on market trends, status and outlook for segments. With comprehensive coverage of the market across different market segments, the report is a valuable asset for the existing players, new entrants and the future investors.

Why buy this report?

Get a detailed picture of the China Therapeutic Antibodies Market  
Identify segments/areas to invest in over the forecast period in the China Therapeutic Antibodies Market  
Understand the competitive environment, the market's leading players  
The market estimate for ease of analysis across scenarios in Excel format.  
Strategy consulting and research support for three months.  
Print authentication provided for the single-user license.

## Contents

Part 1. Summary

Part 2. Introduction

Study period

Geographical scope

Market segmentation

Part 3. Therapeutic antibodies market overview

Part 4. Market breakdown by type

Antibody-drug conjugate (ADC)

BsAb

Monospecific Ab

Others

Part 5. Key companies

3SBio Inc.

Bristol-Myers Squibb Company

Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

Merck & Co.

Novartis International AG

Roche Holding AG

Sinopharm Corporation Ltd.

Part 6. Methodology

## I would like to order

Product name: Therapeutic Antibodies Market in China 2023

Product link: <https://marketpublishers.com/r/T1ED9C894718EN.html>

Price: US\$ 675.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T1ED9C894718EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970